| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.04. | INBS completes clinical study for FDA drug screening submission | 3 | Investing.com | ||
| 02.04. | INBS schließt klinische Studie für FDA-Zulassungsantrag ab | 2 | Investing.com Deutsch | ||
| 02.04. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market | 123 | GlobeNewswire (Europe) | Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for 510(k) submission with method comparison, usability... ► Artikel lesen | |
| 26.03. | Intelligent Bio Solutions receives European patent for drug testing tech | 1 | Investing.com | ||
| INTELLIGENT BIO SOLUTIONS Aktie jetzt für 0€ handeln | |||||
| 26.03. | Intelligent Bio Solutions erhält europäisches Patent für Drogentest-Technologie | 5 | Investing.com Deutsch | ||
| 23.03. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 25.02. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.02. | INBS receives first reader shipment from Syrma Johari partnership | 3 | Investing.com | ||
| 25.02. | Intelligent Bio Solutions erhält erste Lieferung von Lesegeräten aus Syrma-Johari-Partnerschaft | 2 | Investing.com Deutsch | ||
| 25.02. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry | 1 | GlobeNewswire (USA) | ||
| 24.02. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Partners with Bouygues UK, Part of Multi-Billion Dollar Global Construction Giant Bouygues Construction, for UK Drug Testing Rollout | 4 | GlobeNewswire (USA) | ||
| 12.02. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 12.02. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year | 350 | GlobeNewswire (Europe) | First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum... ► Artikel lesen | |
| 12.02. | INTELLIGENT BIO SOLUTIONS INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 05.02. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 05.02. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year | 7 | GlobeNewswire (USA) | ||
| 28.01. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 10 | SEC Filings | ||
| 28.01. | Intelligent Bio Solutions begins clinical studies for FDA clearance | 2 | Investing.com | ||
| 28.01. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market | 173 | GlobeNewswire (Europe) | Clinical studies designed to support FDA clearance and planned commercial launch into the world's largest drug screening market Company anticipates full data analysis by the end of March 2026; data... ► Artikel lesen | |
| 08.01. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 6 | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 15,630 | -0,45 % | Eckert & Ziegler erhält MDR-Zertifizierung für Augentumorbehandlung | Die Eckert & Ziegler BEBIG GmbH, eine auf Brachytherapie spezialisierte Tochtergesellschaft der Eckert & Ziegler SE, hat die MDR-Zertifizierung der EU für ihre Ruthenium-106-Augenapplikatoren erhalten.... ► Artikel lesen | |
| DRAEGERWERK | 95,70 | -1,34 % | Draegerwerk AG & Co. KGaA: Online-Präsentation für Investoren als Teil der German Select 7 Conference am 14.04.2026 | Vor diesem Hintergrund veranstaltet mwb research am 14.04.2026 um 14:00 CEST einen Online-Roundtable mit Thomas Fischler (Head of Treasury & Investor Relations). Nach einer Präsentation besteht die... ► Artikel lesen | |
| TELADOC HEALTH | 4,668 | +4,95 % | Pineal Capital Management Issues Open Letter to the Board of Teladoc Health, Inc. | DUBLIN, March 31, 2026 (GLOBE NEWSWIRE) -- The following is an open letter issued by Pineal Capital Management:
Board of DirectorsTeladoc Health, Inc.2 Manhattanville Road, Suite 203Purchase, NY... ► Artikel lesen | |
| ROKU | 91,40 | +1,16 % | Roku TV vs. Fire Stick: Why I'm looking beyond streaming resolution when comparing the two | ||
| HIMS & HERS HEALTH | 18,330 | +1,05 % | Hims & Hers-Aktie: Neue Chancen nach dem Hype? | Die Aktie von Hims & Hers Health hat nach einer Zeit voller Hype und überschwänglichen Erwartungen in den vergangenen Monaten massiv gelitten. Nach einem deutlichen Kursrückgang rückt nun die Frage... ► Artikel lesen | |
| BICO GROUP | 1,854 | -0,22 % | BICO Group AB: BICO Group AB has divested the Finnish property for a total of EUR 3.5m | BICO Group AB ("BICO") has completed the divestment of its property in Oulu, Finland, through the sale of BICO Real Estate Oy to Logistea AB ("Logistea"). The total sales price amounts to EUR 3.5m,... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,110 | 0,00 % | Sernova Biotherapeutics: Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - April 9, 2026) - Sernova Biotherapeutics Inc. (TSX: SVA) (OTC: SEOVF) (FSE: PSH0) ("Sernova" or the "Company"), a leading regenerative... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,710 | 0,00 % | Geratherm Medical wechselt vom Börsensegment Scale in den Open Market | Die Geratherm Medical AG beendet zum 27. April 2026 die Einbeziehung ihrer Aktien in das Börsensegment Scale der Frankfurter Wertpapierbörse und wechselt ins Basic Board am Open Market. Die Börsennotierung... ► Artikel lesen | |
| SYNLAB | 12,710 | 0,00 % | EQS-News: SYNLAB: Die Region Stockholm beauftragt SYNLAB mit dem Ausbau ihrer medizinischen Diagnostikdienstleistungen in Schweden | EQS-News: SYNLAB
/ Schlagwort(e): Sonstiges
Die Region Stockholm beauftragt SYNLAB mit dem Ausbau ihrer medizinischen Diagnostikdienstleistungen in Schweden
31.03.2026... ► Artikel lesen | |
| ALIGN TECHNOLOGY | 159,55 | +1,79 % | Aktien New York: Weitere Verluste wegen erneutem Ölpreisschub | NEW YORK (dpa-AFX) - An den New Yorker Aktienmärkten geht es am Donnerstag aus Angst vor einer weiteren Eskalation an den Energiemärkten weiter bergab. Deutlich steigende Öl- und Gaspreise im Zuge... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,013 | +24,07 % | NuGen Medical Devices Inc.: NuGen Files Patent for Ready-to-Fill COP/COC Needle-Free Injection Nozzle, Advancing Prefilled Nozzle Technology | Toronto, Ontario--(Newsfile Corp. - March 25, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen"), a leader in needle-free drug delivery, today announced the filing of a new patent covering... ► Artikel lesen | |
| PLUS THERAPEUTICS | 5,300 | -2,39 % | Plus Therapeutics Inc.: Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution | HOUSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals... ► Artikel lesen | |
| HEALWELL AI | 0,525 | +1,35 % | Bloom Burton & Co. Inc.: HEALWELL to Participate in Upcoming 2026 Bloom Burton & Co. Healthcare Investor Conference | 2026 Bloom Burton & Co. Healthcare Investor Conference on April 21-22, 2026, in Toronto, ONToronto, Ontario--(Newsfile Corp. - April 13, 2026) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL"... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,001 | -100,00 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update | SEATTLE, March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| INVITAE | - | - | Patentstreit: Natera sichert sich 30 % Lizenzgebühr von Invitae |